Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma

Chunping Qiu, Yu Wang, Xiao Wang, Qing Zhang, Yinuo Li, Ying Xu, Chengjuan Jin, Hualei Bu, Wenxin - Zheng, Xingsheng Yang, Nan Lu, Beihua Kong

Research output: Contribution to journalArticle

Abstract

Ovarian high-grade serous carcinoma (HGSC) and low-grade serous carcinoma (LGSC) are distinct gynecologic neoplasms with diverse pathogenesis and characteristic features. They respond differently to same modalities of treatment protocol and have dissimilar prognosis. Thus, it is essential to obtain accurate differential diagnosis of HGSC and LGSC prior to clinical treatment. In the present study, mRNA expression profiles were generated from 5 HGSC and 6 LGSC specimen using HTSeq, and 699 differentially expressed genes (>2-fold difference) were identified using the DESeq R package. Dendrograms produced by unsupervised hierarchical clustering completely distinguished HGSC from LGSC. Among differentially expressed genes between HGSC and LGSC, anterior gradient homolog 3 (AGR3) was highly upregulated in LGSC compared to HGSC, which was validated by reverse transcription-quantitative polymerase chain reaction and western blotting. Then, anti-tumor protein 53 (TP53) and anti-AGR3 immunohistochemistry were performed on 145 HGSC and 30 LGSC samples. Consistent with previous studies, abnormal expression of TP53 (0 or ≥75% positive expression) was observed in 87.6% of HGSC and 13.3% of LGSC samples. Positive staining of AGR3 had a sensitivity of 80.0% and specificity of 89.7% for LGSC. TP53 and AGR3 were both efficient in distinguishing HGSC from LGSC (P<0.001). Receiver operating characteristic analysis revealed a similar area under the curve for AGR3 (0.848) and TP53 (0.871). Through combination of the two markers (TP53 wild-type pattern and AGR3-positive expression), the accuracy of differential diagnosis was up to 93.1%. These findings provide compelling evidence that differential diagnosis of HGSC and LGSC can be improved by combined application of these two markers on the basis of conventional histopathological diagnosis.

Original languageEnglish (US)
Pages (from-to)2041-2050
Number of pages10
JournalInternational Journal of Oncology
Volume52
Issue number6
DOIs
StatePublished - Jun 1 2018
Externally publishedYes

Fingerprint

Carcinoma
Neoplasms
Proteins
Differential Diagnosis
Female Genital Neoplasms
Tumor Biomarkers
Clinical Protocols
ROC Curve
Genes
Reverse Transcription
Area Under Curve
Cluster Analysis
Western Blotting
Immunohistochemistry

Keywords

  • Anterior gradient homolog 3
  • Differential diagnosis
  • High-grade serous carcinoma
  • Low-grade serous carcinoma
  • Tumor protein 53

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma. / Qiu, Chunping; Wang, Yu; Wang, Xiao; Zhang, Qing; Li, Yinuo; Xu, Ying; Jin, Chengjuan; Bu, Hualei; Zheng, Wenxin -; Yang, Xingsheng; Lu, Nan; Kong, Beihua.

In: International Journal of Oncology, Vol. 52, No. 6, 01.06.2018, p. 2041-2050.

Research output: Contribution to journalArticle

Qiu, C, Wang, Y, Wang, X, Zhang, Q, Li, Y, Xu, Y, Jin, C, Bu, H, Zheng, W, Yang, X, Lu, N & Kong, B 2018, 'Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma', International Journal of Oncology, vol. 52, no. 6, pp. 2041-2050. https://doi.org/10.3892/ijo.2018.4360
Qiu, Chunping ; Wang, Yu ; Wang, Xiao ; Zhang, Qing ; Li, Yinuo ; Xu, Ying ; Jin, Chengjuan ; Bu, Hualei ; Zheng, Wenxin - ; Yang, Xingsheng ; Lu, Nan ; Kong, Beihua. / Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma. In: International Journal of Oncology. 2018 ; Vol. 52, No. 6. pp. 2041-2050.
@article{b2c5fc50fe314cf9bfa1ea256e837098,
title = "Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma",
abstract = "Ovarian high-grade serous carcinoma (HGSC) and low-grade serous carcinoma (LGSC) are distinct gynecologic neoplasms with diverse pathogenesis and characteristic features. They respond differently to same modalities of treatment protocol and have dissimilar prognosis. Thus, it is essential to obtain accurate differential diagnosis of HGSC and LGSC prior to clinical treatment. In the present study, mRNA expression profiles were generated from 5 HGSC and 6 LGSC specimen using HTSeq, and 699 differentially expressed genes (>2-fold difference) were identified using the DESeq R package. Dendrograms produced by unsupervised hierarchical clustering completely distinguished HGSC from LGSC. Among differentially expressed genes between HGSC and LGSC, anterior gradient homolog 3 (AGR3) was highly upregulated in LGSC compared to HGSC, which was validated by reverse transcription-quantitative polymerase chain reaction and western blotting. Then, anti-tumor protein 53 (TP53) and anti-AGR3 immunohistochemistry were performed on 145 HGSC and 30 LGSC samples. Consistent with previous studies, abnormal expression of TP53 (0 or ≥75{\%} positive expression) was observed in 87.6{\%} of HGSC and 13.3{\%} of LGSC samples. Positive staining of AGR3 had a sensitivity of 80.0{\%} and specificity of 89.7{\%} for LGSC. TP53 and AGR3 were both efficient in distinguishing HGSC from LGSC (P<0.001). Receiver operating characteristic analysis revealed a similar area under the curve for AGR3 (0.848) and TP53 (0.871). Through combination of the two markers (TP53 wild-type pattern and AGR3-positive expression), the accuracy of differential diagnosis was up to 93.1{\%}. These findings provide compelling evidence that differential diagnosis of HGSC and LGSC can be improved by combined application of these two markers on the basis of conventional histopathological diagnosis.",
keywords = "Anterior gradient homolog 3, Differential diagnosis, High-grade serous carcinoma, Low-grade serous carcinoma, Tumor protein 53",
author = "Chunping Qiu and Yu Wang and Xiao Wang and Qing Zhang and Yinuo Li and Ying Xu and Chengjuan Jin and Hualei Bu and Zheng, {Wenxin -} and Xingsheng Yang and Nan Lu and Beihua Kong",
year = "2018",
month = "6",
day = "1",
doi = "10.3892/ijo.2018.4360",
language = "English (US)",
volume = "52",
pages = "2041--2050",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma

AU - Qiu, Chunping

AU - Wang, Yu

AU - Wang, Xiao

AU - Zhang, Qing

AU - Li, Yinuo

AU - Xu, Ying

AU - Jin, Chengjuan

AU - Bu, Hualei

AU - Zheng, Wenxin -

AU - Yang, Xingsheng

AU - Lu, Nan

AU - Kong, Beihua

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Ovarian high-grade serous carcinoma (HGSC) and low-grade serous carcinoma (LGSC) are distinct gynecologic neoplasms with diverse pathogenesis and characteristic features. They respond differently to same modalities of treatment protocol and have dissimilar prognosis. Thus, it is essential to obtain accurate differential diagnosis of HGSC and LGSC prior to clinical treatment. In the present study, mRNA expression profiles were generated from 5 HGSC and 6 LGSC specimen using HTSeq, and 699 differentially expressed genes (>2-fold difference) were identified using the DESeq R package. Dendrograms produced by unsupervised hierarchical clustering completely distinguished HGSC from LGSC. Among differentially expressed genes between HGSC and LGSC, anterior gradient homolog 3 (AGR3) was highly upregulated in LGSC compared to HGSC, which was validated by reverse transcription-quantitative polymerase chain reaction and western blotting. Then, anti-tumor protein 53 (TP53) and anti-AGR3 immunohistochemistry were performed on 145 HGSC and 30 LGSC samples. Consistent with previous studies, abnormal expression of TP53 (0 or ≥75% positive expression) was observed in 87.6% of HGSC and 13.3% of LGSC samples. Positive staining of AGR3 had a sensitivity of 80.0% and specificity of 89.7% for LGSC. TP53 and AGR3 were both efficient in distinguishing HGSC from LGSC (P<0.001). Receiver operating characteristic analysis revealed a similar area under the curve for AGR3 (0.848) and TP53 (0.871). Through combination of the two markers (TP53 wild-type pattern and AGR3-positive expression), the accuracy of differential diagnosis was up to 93.1%. These findings provide compelling evidence that differential diagnosis of HGSC and LGSC can be improved by combined application of these two markers on the basis of conventional histopathological diagnosis.

AB - Ovarian high-grade serous carcinoma (HGSC) and low-grade serous carcinoma (LGSC) are distinct gynecologic neoplasms with diverse pathogenesis and characteristic features. They respond differently to same modalities of treatment protocol and have dissimilar prognosis. Thus, it is essential to obtain accurate differential diagnosis of HGSC and LGSC prior to clinical treatment. In the present study, mRNA expression profiles were generated from 5 HGSC and 6 LGSC specimen using HTSeq, and 699 differentially expressed genes (>2-fold difference) were identified using the DESeq R package. Dendrograms produced by unsupervised hierarchical clustering completely distinguished HGSC from LGSC. Among differentially expressed genes between HGSC and LGSC, anterior gradient homolog 3 (AGR3) was highly upregulated in LGSC compared to HGSC, which was validated by reverse transcription-quantitative polymerase chain reaction and western blotting. Then, anti-tumor protein 53 (TP53) and anti-AGR3 immunohistochemistry were performed on 145 HGSC and 30 LGSC samples. Consistent with previous studies, abnormal expression of TP53 (0 or ≥75% positive expression) was observed in 87.6% of HGSC and 13.3% of LGSC samples. Positive staining of AGR3 had a sensitivity of 80.0% and specificity of 89.7% for LGSC. TP53 and AGR3 were both efficient in distinguishing HGSC from LGSC (P<0.001). Receiver operating characteristic analysis revealed a similar area under the curve for AGR3 (0.848) and TP53 (0.871). Through combination of the two markers (TP53 wild-type pattern and AGR3-positive expression), the accuracy of differential diagnosis was up to 93.1%. These findings provide compelling evidence that differential diagnosis of HGSC and LGSC can be improved by combined application of these two markers on the basis of conventional histopathological diagnosis.

KW - Anterior gradient homolog 3

KW - Differential diagnosis

KW - High-grade serous carcinoma

KW - Low-grade serous carcinoma

KW - Tumor protein 53

UR - http://www.scopus.com/inward/record.url?scp=85045381858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045381858&partnerID=8YFLogxK

U2 - 10.3892/ijo.2018.4360

DO - 10.3892/ijo.2018.4360

M3 - Article

VL - 52

SP - 2041

EP - 2050

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -